The top research and development executives from across biopharma are certainly not looking down the back of the sofa for change; most are earning around $7 million a year. But then the job is tough, and arguably just as important as the top CEO job, given how much companies rely on the strength of their R&D.
Lung cancer patients taking Rova-T as a frontline treatment didn't live longer than those on placebo, prompting AbbVie to end the study and dump Rova-T.
